MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Clinical trials for MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to improve myelofibrosis treatment
Disease control Recruiting nowThis early-phase study tests whether adding abemaciclib to the standard drug ruxolitinib is safe and effective for people with myelofibrosis, a type of bone marrow cancer. About 18 adults who have been on ruxolitinib for at least 12 weeks will take both drugs. The goal is to find…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:31 UTC
-
New drug aims to free blood cancer patients from transfusions
Disease control Recruiting nowThis study is testing an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can help patients produce enough red blood cells so they no longer need regular blood transfus…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Phase: PHASE1, PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC